209 related articles for article (PubMed ID: 33581599)
1. Appropriate use of generic and branded antiseizure medications in epilepsy: Updated recommendations from the Italian League Against Epilepsy (LICE).
Roberti R; Casarella A; Iudice A; La Neve A; Beghi E; Capovilla G; Di Bonaventura C; Giorgi FS; Grosso S; Iannone LF; Romigi A; Specchio LM; Zaccara G; Mecarelli O; Russo E;
Epilepsy Behav; 2021 Mar; 116():107804. PubMed ID: 33581599
[TBL] [Abstract][Full Text] [Related]
2. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Basis of Generic Substitution of Antiseizure Medications.
Elmer S; Reddy DS
J Pharmacol Exp Ther; 2022 May; 381(2):188-196. PubMed ID: 35241634
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe.
Odi R; Franco V; Perucca E; Bialer M
Epilepsia; 2021 Feb; 62(2):285-302. PubMed ID: 33426641
[TBL] [Abstract][Full Text] [Related]
5. Alternatives to valproate in girls and women of childbearing potential with Idiopathic Generalized Epilepsies: state of the art and guidance for the clinician proposed by the Epilepsy and Gender Commission of the Italian League Against Epilepsy (LICE).
Mostacci B; Ranzato F; Giuliano L; La Neve A; Aguglia U; Bilo L; Durante V; Ermio C; Monti G; Zambrelli E; Lodi MAM; Galimberti CA
Seizure; 2021 Feb; 85():26-38. PubMed ID: 33418162
[TBL] [Abstract][Full Text] [Related]
6. Current approaches to the use of generic antiepileptic drugs.
Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G
Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678
[TBL] [Abstract][Full Text] [Related]
7. Use of antiseizure medications and safety of branded versus generic formulations: A comparative study on Tuscan administrative databases.
Giometto S; Baglietto L; Conte M; Vannacci A; Tuccori M; Mugelli A; Gini R; Lucenteforte E
Epilepsy Behav; 2021 Apr; 117():107876. PubMed ID: 33714929
[TBL] [Abstract][Full Text] [Related]
8. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.
Bialer M; Midha KK
Epilepsia; 2010 Jun; 51(6):941-50. PubMed ID: 20384761
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications.
Asadi-Pooya AA; Patel AA; Trinka E; Mazurkiewicz-Beldzinska M; Cross JH; Welty TE
Epileptic Disord; 2022 Oct; 24(5):751-764. PubMed ID: 35894673
[TBL] [Abstract][Full Text] [Related]
11. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Makus KG; McCormick J
Clin Ther; 2007 Feb; 29(2):334-41. PubMed ID: 17472825
[TBL] [Abstract][Full Text] [Related]
12. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
Holtkamp M; Theodore WH
Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
[TBL] [Abstract][Full Text] [Related]
13. Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
Straka RJ; Keohane DJ; Liu LZ
Am J Ther; 2017 May; 24(3):e278-e289. PubMed ID: 26099048
[TBL] [Abstract][Full Text] [Related]
14. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Andermann F; Duh MS; Gosselin A; Paradis PE
Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
[TBL] [Abstract][Full Text] [Related]
15. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
[TBL] [Abstract][Full Text] [Related]
16. Evolution of antiseizure medication use and cost in the United States of America 2006-2021.
Sánchez Fernández I; Gaínza-Lein M; Amengual-Gual M; Barcia Aguilar C; Romeu A; Torres A; Jonas R; Douglass LM
Seizure; 2023 Nov; 112():128-138. PubMed ID: 37832279
[TBL] [Abstract][Full Text] [Related]
17. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
18. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
19. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
[TBL] [Abstract][Full Text] [Related]
20. An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong.
Fong JK; Chan EL; Leung H; Chan I; Chang RS; Fong GC; Fung EL; Lui CH; Fung BB; Poon TL; Siu D; Wong HT; Yeung E; Yung AW; Zhu CX;
Hong Kong Med J; 2017 Feb; 23(1):74-88. PubMed ID: 28184017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
